Stereotaxis Inc. (STXS)
STXS trades on NYSE in Health Care, Biotechnology: Electromedical & Electrotherapeutic Apparatus. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1289340/000149315226009881/0001493152-26-009881-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | STXS on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001289340 |
| SEC industry code | Electromedical & Electrotherapeutic Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $32.4M |
| Net income | -$21.6M |
| Operating income | -$22.1M |
| Net margin | -66.8% |
| Operating margin | -68.3% |
| Revenue growth | +20.3% |
| Cash | $13.4M |
| Total assets | $52.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-12 |
| Cash and burn | $10.5M cash; operating cash flow -$3.8M a quarter. | Report 2026-06-30 |
| Shares outstanding | 100,202,178 (2026-07-31); 90,653,769 a year earlier; 80,868,280 three years earlier. | Cover page 2026-07-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 3 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-07-15 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Saint Louis, Missouri, United States | PCAOB Form AP 2026-04-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $67K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $7.7M | -$4.5M | -$3.7M | $10.5M | No debt tags | $30.1M | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | $6.3M | -$5.9M | -$3.4M | $14.6M | No debt tags | $31.2M | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $8.6M | -$5.5M | -$4.0M | $13.4M | No debt tags | $32.4M | 10-K 2026-03-12 |
| Q3 2025 2025-09-30 | $7.5M | -$6.5M | -$4.2M | $10.5M | No debt tags | $30.1M | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | $8.8M | -$3.8M | -$3.7M | $7.0M | No debt tags | $31.8M | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | $7.5M | -$5.8M | -$1.8M | $10.6M | No debt tags | $27.5M | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $6.3M | -$7.5M | $1.3M | $12.2M | No debt tags | $26.9M | 10-K 2026-03-12 |
| Q3 2024 2024-09-30 | $9.2M | -$6.2M | -$4.3M | $10.7M | No debt tags | $25.1M | 10-Q 2025-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-08-13 |
| Latest annual report | 10-K/A | 2026-04-03 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEFA14A | 2026-04-03 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -22.9% |
| 1 month | -20.8% |
| 3 months | -39.1% |
| Year to date | -63.5% |
| 1 year | -62.5% |
| From 52-week high | -69.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Electromedical & Electrotherapeutic Apparatus
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VANI | Vivani Medical Inc. Common Stock (DE) | $1.02 | +0.99% | $92.0M |
| NRXS | Neuraxis Inc. | $4.80 | -11.44% | $68.1M |
| HYPR | Hyperfine Inc. | $0.6101 | -3.05% | $64.8M |
| OM | Outset Medical Inc. | $3.39 | -9.12% | $64.0M |
| HSDT | Solana Company Class A Common Stock (DE) | $1.64 | -5.20% | $103.1M |
| POCI | Precision Optics Corporation Inc. | $4.97 | -4.97% | $54.6M |
| ECOR | electroCore Inc. | $4.84 | -7.81% | $44.7M |
| FOCL | EDAP TMS S.A. | $3.17 | -2.39% | $149.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier